|
|
News Breaks | | | | December 24, 2012 | | 08:04 EDT |  | RPTP | Raptor Pharma weakness may provide buying opporutnity, says Oppenheimer
After Raptor announced that the FDA had postponed its decision on approving Raptor's Procysbi for three months until April 30, 2013, Oppneheimer views the news as a short-term negative for the company but doesn't think it has any implication on the FDA's ultimate decision about Procysbi. The firm maintains an Outperform rating on Raptor. | |
|
News For RPTP From The Last 14 Days Check below for free stories on RPTP the last two weeks. |
|
|
| There are no results for RPTP |
|
|
|
|
|
|
